[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533095":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":41,"collaborators":7,"id":44,"slug":7,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Calgary","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Chad Bousman, MPH, PhD","PRINCIPAL_INVESTIGATOR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Weng-Sam Siu, MSPT, MSc","CONTACT","5875739747","sam.siu@ucalgary.ca",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},"Madison Heintz, MSW","psychpgxlab@ucalgary.ca",[22],{"facility":5,"status":23,"city":24,"state":25,"zip":7,"country":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Calgary","Alberta","Canada",{"type":28,"coordinates":29},"Point",[30,31],-114.08529,51.05011,{"lat":31,"lon":30},[34,35,36,39],{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":37,"role":38,"phone":7,"phoneExt":7,"email":7},"Kara Murias, MD, PhD","SUB_INVESTIGATOR",{"name":40,"role":38,"phone":7,"phoneExt":7,"email":7},"Paul Arnold, MD, PhD",{"type":11,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Chad Bousman","Associate Professor","100533095",false,"NCT06221358","Pharmacogenomics of Stimulant Treatment Response","Pharmacogenomics of Stimulant Treatment Response in Children and Adolescents With Attention-Deficit\u002F Hyperactivity Disorder","PGx-STaR","Inclusion Criteria:\n\nPatients will be eligible for participation if all the following are true.\n\n* Aged 6 - 24 years.\n* Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).\n* Primary diagnosis of ADHD (all types).\n* Starting Methylphenidate (excluding immediate release forms) treatment.\n\nExclusion Criteria:\n\nPatients will be excluded from participation if any of the following are true.\n\n* Co-occurring psychotic, bipolar or eating disorders.\n* Significant risk of suicide.\n* An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics\u002FTourette disorders.\n* Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.\n* Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate\u002Fchange these types of therapies during the study\n* History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.","ALL","6 Years","24 Years",{"count":55,"type":56},400,"ESTIMATED","OBSERVATIONAL","The \"Pharmacogenomics of Stimulant Treatment Response\" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit\u002Fhyperactivity disorder (ADHD).",[60],"Attention-Deficit\u002F Hyperactivity Disorder (ADHD)",[62,63,64,65,66,67,68],"Children","Adolescents","ADHD","Pharmacogenetics","Neurology","Psychostimulants","Methylphenidate","2025-11-27",{"date":71,"type":72},"2025-12-05","ACTUAL",{"date":74,"type":72},"2024-04-01",{"date":76,"type":56},"2028-12-31",{"name":5,"class":6},1]